Engineering of the epigenome: Synthetic biology to define functional causality and develop innovative therapies

Epigenomics

Volumn 8, Issue 2, 2016, Pages 153-156

  Tost, Jörg ^a  

^a CENTRE NATIONAL DE GÉNOTYPAGE   (France)

Author keywords

artificial transcription factors; CRISPR Cas9; DNMT; epigenome editing; KRAB; LSD1; synthetic biology; TALEs; TET; zinc fingers

Indexed keywords

DNA METHYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; TRANSCRIPTION FACTOR;

ALLERGIC DISEASE; AUTOIMMUNE DISEASE; CRISPR CAS SYSTEM; DNA METHYLATION; EPIGENETICS; EXPERIMENTAL THERAPY; GENE; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HISTONE MODIFICATION; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNTHETIC BIOLOGY; DRUG DEVELOPMENT; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETIC EPIGENESIS; PROCEDURES;

DRUG DISCOVERY; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; HUMANS;

EID: 84959360518     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.112     Document Type: Review

References (22)

1. de Groote ML, Verschure PJ, Rots MG. Epigenetic editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res. 40(21), 10596-10613 (2012).
2. Carroll D. Genome engineering with targetable nucleases. Annu. Rev. Biochem. 83, 409-439 (2014).
3. Jurkowski TP, Ravichandran M, Stepper P. Synthetic epigenetics-towards intelligent control of epigenetic states and cell identity. Clin. Epigenet. 7(1), 18 (2015).
4. Laufer BI, Singh SM. Strategies for precision modulation of gene expression by epigenome editing: an overview. Epigenet. Chromatin 8, 34 (2015).
5. Chen H, Kazemier HG, de Groote ML, Ruiters MH, Xu GL, Rots MG. Induced DNA demethylation by targeting ten-eleven translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res. 42(3), 1563-1574 (2014).
6. Maeder ML, Angstman JF, Richardson ME et al. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat. Biotechnol. 31(12), 1137-1142 (2013).
7. Siddique AN, Nunna S, Rajavelu A et al. Targeted methylation and gene silencing of VEGF-A in human cells by using a designed DNMT3a-DNMT3L single-chain fusion protein with increased DNA methylation activity. J. Mol. Biol. 425(3), 479-491 (2013).
8. Nunna S, Reinhardt R, Ragozin S, Jeltsch A. Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells. PLoS ONE 9(1), e87703 (2014).
9. Falahi F, Huisman C, Kazemier HG et al. Towards sustained silencing of HER2/neu in cancer by epigenetic editing. Mol. Cancer Res. 11(9), 1029-1039 (2013).
10. Bernstein DL, Le Lay JE, Ruano EG, Kaestner KH. TALEmediated epigenetic suppression of CDKN2A increases replication in human fibroblasts. J. Clin. Invest. 125(5), 1998-2006 (2015).
11. Mendenhall EM, Williamson KE, Reyon D et al. Locusspecific editing of histone modifications at endogenous enhancers. Nat. Biotechnol. 31(12), 1133-1136 (2013).
12. Fanucchi S, Shibayama Y, Burd S, Weinberg MS, Mhlanga MM. Chromosomal contact permits transcription between coregulated genes. Cell 155(3), 606-620 (2013).
13. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6), 1262-1278 (2014).
14. Swiech L, Heidenreich M, Banerjee A et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 33(1), 102-106 (2015).
15. Narendra V, Rocha PP, An D et al. Transcription. CTCF establishes discrete functional chromatin domains at the Hox clusters during differentiation. Science 347(6225), 1017-1021 (2015).
16. Hilton IB, D'Ippolito AM, Vockley CM et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat. Biotechnol. 33(5), 510-517 (2015).
17. Kearns NA, Pham H, Tabak B et al. Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat. Methods 12(5), 401-403 (2015).
18. Jo YI, Suresh B, Kim H, Ramakrishna S. CRISPR/Cas9 system as an innovative genetic engineering tool: enhancements in sequence specificity and delivery methods. Biochim. Biophys. Acta 1856(2), 234-243 (2015).
19. Thakore PI, D'Ippolito AM, Song L et al. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat. Methods 1856(2), 234-243 (2015).
20. Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J. CRISPR-Cas9: A new and promising player in gene therapy. J. Med. Genet. 52(5), 289-296 (2015).
21. Peeters JG, Vervoort SJ, Tan SC et al. Inhibition of superenhancer activity in autoinflammatory site-derived T cells reduces disease-associated gene expression. Cell Rep. 12(12), 1986-1996 (2015).
22. Liu Y, Zeng Y, Liu L et al. Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nat. Commun. 5, 5393 (2014).